Professor | Ming Liu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Ming Liu
Contact Information	liuming@gzhmu.edu.cn
Language ability	English, Chinese
Province	Guangdong

Upload Avatar (500 x 500)

Name

Ming Liu

Contact Information

liuming@gzhmu.edu.cn

Language ability

English, Chinese

Province

Guangdong

University/Lab Affiliation and Title	Guangzhou Medical University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2013 - PhD: The University of Hong Kong Outstanding Graduate: The University of Hong Kong
Work Experience	2014-2016 - The University of Hong Kong - Postdoctoral Researcher 2016-present - Guangzhou Medical University - Professor, Doctoral Supervisor
Awards	2018: Guangdong Province Higher Education 'Young Pearl River Scholar' 2017: Guangdong Province 'Pearl River Talent Plan' Young Top Talent 2015: Ministry of Education of the People's Republic of China Natural Science Second Prize (Fifth Contributor) 2014: Hong Kong Young Scientist Award 2014: The University of Hong Kong 'Dr KP Stephen Chang' Gold Medal 2013: The University of Hong Kong 'Yu To Sang and Yu Shing Keung' Cancer Research Memorial Fund Award 2013: The University of Hong Kong 'Mary Sun' Medical Research Award 2013: The University of Hong Kong 'YS and Christabel Lung' Medical Research Award

University/Lab Affiliation and Title

Guangzhou Medical University

Faculty

Basic Medical Sciences

Academic Background & Achievements

2013 - PhD: The University of Hong Kong
Outstanding Graduate: The University of Hong Kong

Work Experience

2014-2016 - The University of Hong Kong - Postdoctoral Researcher
2016-present - Guangzhou Medical University - Professor, Doctoral Supervisor

Awards

2018: Guangdong Province Higher Education 'Young Pearl River Scholar'
2017: Guangdong Province 'Pearl River Talent Plan' Young Top Talent
2015: Ministry of Education of the People's Republic of China Natural Science Second Prize (Fifth Contributor)
2014: Hong Kong Young Scientist Award
2014: The University of Hong Kong 'Dr KP Stephen Chang' Gold Medal
2013: The University of Hong Kong 'Yu To Sang and Yu Shing Keung' Cancer Research Memorial Fund Award
2013: The University of Hong Kong 'Mary Sun' Medical Research Award
2013: The University of Hong Kong 'YS and Christabel Lung' Medical Research Award

Areas of Focus	Exploring molecular mechanisms of tumor plasticity and heterogeneity leading to drug resistance and immune evasion Screening molecular markers and potential anti-tumor drug targets for monitoring malignant tumor progression Developing innovative drugs and therapeutic strategies targeting tumor plasticity
Publications	Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate., Kong FE, Li GM, Tang YQ, Xi SY, Loong JHC, Li MM, Li HL, Cheng W, Zhu WJ, Mo JQ, Gong YF, Tang H, Zhao Y, Zhang Y, Ma S, Guan XY, Ma NF, Xie MB, Liu M., 2021 PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma., Yang XD, Kong FE, Qi L, Lin JX, Yan Q, Loong JHC, Xi SY, Zhao Y, Zhang Y, Yuan YF, Ma NF, Ma S, Guan XY, Liu M., 2021 A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets., Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JHC, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang LX, Fang S, Yang XD, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang JG, Guan XY., 2020 Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway., Fang S, Liu M, Li L, Zhang FF, Li Y, Yan Q, Cui YZ, Zhu YH, Yuan YF, Guan XY., 2019 CHD1L Promotes Lineage Reversion of Hepatocellular Carcinoma through Opening Chromatin for Key Developmental Transcription Factors., Liu M, Chen L, Ma NF, Chow RK, Li Y, Song Y, Chan TH, Fang S, Yang X, Xi S, Jiang L, Li Y, Zeng TT, Li Y, Yuan YF, Guan XY., 2016 The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update., Liu M, Jiang L, Guan XY., 2014 Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma., Liu M, Li Y, Chen L, Chan TH, Song Y, Fu L, Zeng TT, Dai YD, Zhu YH, Li Y, Chen J, Yuan YF, Guan XY., 2014 Serum and glucocorticoid kinase 3 at 8q13.1 promote cell proliferation and survival in hepatocellular carcinoma., Liu M, Chen LL, Chan TH, Wang J, Li Y, Li Y, Zeng TT, Yuan YF, Guan XY., 2012

Areas of Focus

Exploring molecular mechanisms of tumor plasticity and heterogeneity leading to drug resistance and immune evasion
Screening molecular markers and potential anti-tumor drug targets for monitoring malignant tumor progression
Developing innovative drugs and therapeutic strategies targeting tumor plasticity

Publications

Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate., Kong FE, Li GM, Tang YQ, Xi SY, Loong JHC, Li MM, Li HL, Cheng W, Zhu WJ, Mo JQ, Gong YF, Tang H, Zhao Y, Zhang Y, Ma S, Guan XY, Ma NF, Xie MB, Liu M., 2021
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma., Yang XD, Kong FE, Qi L, Lin JX, Yan Q, Loong JHC, Xi SY, Zhao Y, Zhang Y, Yuan YF, Ma NF, Ma S, Guan XY, Liu M., 2021
A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets., Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JHC, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang LX, Fang S, Yang XD, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang JG, Guan XY., 2020
Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway., Fang S, Liu M, Li L, Zhang FF, Li Y, Yan Q, Cui YZ, Zhu YH, Yuan YF, Guan XY., 2019
CHD1L Promotes Lineage Reversion of Hepatocellular Carcinoma through Opening Chromatin for Key Developmental Transcription Factors., Liu M, Chen L, Ma NF, Chow RK, Li Y, Song Y, Chan TH, Fang S, Yang X, Xi S, Jiang L, Li Y, Zeng TT, Li Y, Yuan YF, Guan XY., 2016
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update., Liu M, Jiang L, Guan XY., 2014
Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma., Liu M, Li Y, Chen L, Chan TH, Song Y, Fu L, Zeng TT, Dai YD, Zhu YH, Li Y, Chen J, Yuan YF, Guan XY., 2014
Serum and glucocorticoid kinase 3 at 8q13.1 promote cell proliferation and survival in hepatocellular carcinoma., Liu M, Chen LL, Chan TH, Wang J, Li Y, Li Y, Zeng TT, Yuan YF, Guan XY., 2012

Tumor Plasticity Heterogeneity Drug Resistance Immune Evasion Molecular Mechanisms Tumor Progression Molecular Markers Anti-Tumor Drugs Therapeutic Strategies Clinical Translation

Zhang Jin - Zhejiang University

Fang Xu - Guangzhou Medical University

Zhan Jun - Peking University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us